March 12, 2015
March 12, 2015 – Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced the completion of an $80 million Series B financing. Foresite Capital led the round, with participation from existing investor Longitude Capital and new investors Fidelity Management & Research Company, Aisling Capital, Adage Capital, RA Capital Management and Palo Alto Investors. Allergen press release. FLG partner: Victor Colunga.
Recent News
Cap Hill Brands Merges with Juvo+ to form Infinite Commerce
March 8, 2024 (Geekwire.com) – Seattle-based Cap Hill Brands, which raised more than $250 million to acquire and grow e-commerce shops, has merged with Juvo+, a company that focuses on developing and selling its own products online. Terms of the all-stock deal were not disclosed. The combined company is now…Read More
Read More
